3月28日 - ** 制药商PTC Therapeutics PTCT.O股价下跌1%至54.38美元
** PTCT表示，欧盟委员会已决定不再延长该公司肌肉萎缩症药物Translarna的 (link) 营销授权，该药物将不再在欧盟销售。
** 该药物曾于2014年在欧盟获得有条件批准，用于治疗五岁及以上能行走的杜兴氏肌肉萎缩症患儿
** 公司表示计划与各国单独合作，尽可能保持该药物的商业供应
** TD Cowen 分析师 Joseph Thome 预计 Translarna 2025 年的销售额为 1.92 亿美元，"欧盟的贡献微乎其微"。
** 截至上次收盘，股价在过去 12 个月中上涨了 86.8
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.